{"id":341907,"date":"2025-08-20T15:56:00","date_gmt":"2025-08-20T15:56:00","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-janux-therapeutics\/"},"modified":"2025-08-20T15:56:00","modified_gmt":"2025-08-20T15:56:00","slug":"how-to-buy-janux-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/","title":{"rendered":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-341907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"2025 piyasa f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile Janux Therapeutics (JANX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"2025 piyasa f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile Janux Therapeutics (JANX) hisselerine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisi devriminin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Janux Therapeutics, bilimin hayat de\u011fi\u015ftiren hasta sonu\u00e7lar\u0131yla bulu\u015ftu\u011fu imm\u00fcnoterapi yenili\u011finin \u00f6n saflar\u0131n\u0131 temsil ediyor. B\u00fcy\u00fcyen biyotek sekt\u00f6r\u00fcne maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Janux Therapeutics, Inc. (JANX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 anlamak, portf\u00f6y\u00fcn\u00fczde \u00f6nemli b\u00fcy\u00fcme potansiyelini a\u00e7abilir. Bu sadece hisse senedi ticaretiyle ilgili de\u011fil\u2014t\u0131bbi ilerlemenin bir par\u00e7as\u0131 olmakt\u0131r.","intro_source":{"label":"Intro","type":"text","formatted_value":"Bir sonraki \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisi devriminin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Janux Therapeutics, bilimin hayat de\u011fi\u015ftiren hasta sonu\u00e7lar\u0131yla bulu\u015ftu\u011fu imm\u00fcnoterapi yenili\u011finin \u00f6n saflar\u0131n\u0131 temsil ediyor. B\u00fcy\u00fcyen biyotek sekt\u00f6r\u00fcne maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Janux Therapeutics, Inc. (JANX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 anlamak, portf\u00f6y\u00fcn\u00fczde \u00f6nemli b\u00fcy\u00fcme potansiyelini a\u00e7abilir. Bu sadece hisse senedi ticaretiyle ilgili de\u011fil\u2014t\u0131bbi ilerlemenin bir par\u00e7as\u0131 olmakt\u0131r."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla Janux Therapeutics (JANX) hisseleri <strong>24,70 $<\/strong> seviyesinde i\u015flem g\u00f6rmekte olup, 52 haftal\u0131k aral\u0131\u011f\u0131n\u0131n 21,97 $ ile 71,71 $ aras\u0131ndaki alt s\u0131n\u0131r\u0131na yak\u0131n konumlanm\u0131\u015ft\u0131r. Bu fiyat noktas\u0131, \u015firketin uzun vadeli vizyonuna inanan yat\u0131r\u0131mc\u0131lar i\u00e7in ilgi \u00e7ekici bir giri\u015f f\u0131rsat\u0131 sunmaktad\u0131r.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin\u2014bir sonraki kazan\u00e7 a\u00e7\u0131klama tarihi. Tarihsel veriler, JANX'in \u00e7eyreklik raporlar etraf\u0131nda \u00f6nemli fiyat hareketleri ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. 7 A\u011fustos 2025'teki \u00f6nceki kazan\u00e7lar %17 EPS sapmas\u0131yla sonu\u00e7land\u0131 (-0,55 $ ger\u00e7ekle\u015fen vs. -0,47 $ beklenen), ancak analist g\u00f6r\u00fc\u015fleri 12 al\u0131m ve sadece bir tut \u00f6nerisi ile h\u00e2l\u00e2 son derece olumlu.<\/p> <h3>Kazan\u00e7 Tepkisi Tarih\u00e7esi Analizi<\/h3> <p>Son alt\u0131 kazan\u00e7 olay\u0131n\u0131 incelemek ilgin\u00e7 desenler ortaya koymaktad\u0131r:<\/p> <table> <thead> <tr> <th>Tarih<\/th> <th>Olay<\/th> <th>Haber \u00d6ncesi Fiyat<\/th> <th>Haber Sonras\u0131 De\u011fi\u015fim<\/th> <th>\u00d6nemli \u0130\u00e7g\u00f6r\u00fc<\/th> <\/tr> <\/thead> <tbody> <tr> <td>7 A\u011fu 2025<\/td> <td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>25,50 $<\/td> <td>%-3,1 (1 hafta)<\/td> <td>EPS sapmas\u0131 ancak analist g\u00fcveni korundu<\/td> <\/tr> <tr> <td>8 May 2025<\/td> <td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>28,40 $<\/td> <td>%+5,6 (3 g\u00fcn)<\/td> <td>Beklentileri %2,56 a\u015ft\u0131<\/td> <\/tr> <tr> <td>27 \u015eub 2025<\/td> <td>4. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>32,10 $<\/td> <td>%+8,2 (1 hafta)<\/td> <td>\u00d6nemli %20 EPS a\u015f\u0131m\u0131<\/td> <\/tr> <tr> <td>5 Kas 2024<\/td> <td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>45,20 $<\/td> <td>%-18,3 (2 hafta)<\/td> <td>B\u00fcy\u00fck %54,55 EPS sapmas\u0131<\/td> <\/tr> <tr> <td>8 A\u011fu 2024<\/td> <td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>48,70 $<\/td> <td>%+12,1 (1 hafta)<\/td> <td>G\u00fc\u00e7l\u00fc klinik ilerleme g\u00fcncellemesi<\/td> <\/tr> <tr> <td>9 May 2024<\/td> <td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>42,30 $<\/td> <td>%-6,8 (5 g\u00fcn)<\/td> <td>Karma\u015f\u0131k deneme sonu\u00e7lar\u0131 tepkisi<\/td> <\/tr> <\/tbody> <\/table> <p>Desen, kazan\u00e7 sapmalar\u0131n\u0131n k\u0131sa vadeli volatiliteye neden oldu\u011funu ancak hissenin klinik pipeline ilerlemesine ba\u011fl\u0131 olarak \u00e7eyreklik finansal performanstan ba\u011f\u0131ms\u0131z \u015fekilde toparlanma e\u011filiminde oldu\u011funu g\u00f6stermektedir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2> <p>Janux Therapeutics, son alt\u0131 ayda yakla\u015f\u0131k <strong>%63<\/strong> d\u00fc\u015f\u00fc\u015f ya\u015fayarak Aral\u0131k 2024 zirvesi olan 66,83 $ seviyesinden geriledi. Ancak, son d\u00f6nemdeki istikrar potansiyel dip olu\u015fumuna i\u015faret etmektedir:<\/p> <ul> <li><strong>Ocak 2025<\/strong>: 61,59 $ ile ba\u015flad\u0131, 39,33 $ ile kapand\u0131 (-%18,79) - Tatil sonras\u0131 d\u00fczeltme<\/li> <li><strong>\u015eubat 2025<\/strong>: 31,69 $-45,79 $ aral\u0131\u011f\u0131nda (-%24,36) - Biyotek sekt\u00f6r\u00fcndeki zay\u0131flama devam etti<\/li> <li><strong>Mart 2025<\/strong>: 26,39 $-33,49 $ aral\u0131\u011f\u0131nda istikrar sa\u011flad\u0131 (-%17,91) - \u0130lk destek bulundu<\/li> <li><strong>Nisan 2025<\/strong>: 22,52 $'den 33,51 $'e y\u00fckseldi (+%22,96) - Ar-Ge G\u00fcn\u00fc iyimserli\u011fi<\/li> <li><strong>May\u0131s 2025<\/strong>: 22,48 $-33,97 $ aral\u0131\u011f\u0131nda geri \u00e7ekilme (-%28,31) - Kar realizasyonu a\u015famas\u0131<\/li> <li><strong>Haziran 2025<\/strong>: 22,54 $-27,28 $ aral\u0131\u011f\u0131nda konsolidasyon (-%2,94) - Taban olu\u015fturma<\/li> <li><strong>Temmuz 2025<\/strong>: 22,74 $'den 26,39 $'e toparlanma (+%13,33) - Tersine d\u00f6n\u00fc\u015f\u00fcn erken i\u015faretleri<\/li> <\/ul> <p>Hisse, 22-25 $ aral\u0131\u011f\u0131nda g\u00fc\u00e7l\u00fc destek olu\u015fturuyor gibi g\u00f6r\u00fcnmekte ve son y\u00fckseli\u015f momentumu a\u015f\u0131r\u0131 sat\u0131m ko\u015fullar\u0131ndan potansiyel d\u00f6n\u00fc\u015f\u00fc i\u015faret etmektedir.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik pipeline ilerlemesine dayanarak, gelecekte \u015funlar beklenebilir:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 40-55 $ aral\u0131\u011f\u0131 (+%62 ila +%123) - <strong>AL<\/strong> \u00f6nerisi<br> Kataliz\u00f6rler: Ek JANX007 veri sunumlar\u0131, ARM platformu IND ilerlemesi<\/li> <li><strong>2026 Hedefi<\/strong>: 65-85 $ aral\u0131\u011f\u0131 (+%163 ila +%244)<br> Potansiyel: Faz 2 veri sonu\u00e7lar\u0131, ortakl\u0131k geni\u015flemeleri<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 90-130 $ aral\u0131\u011f\u0131 (+%264 ila +%426)<br> B\u00fcy\u00fcme fakt\u00f6rleri: Olas\u0131 ilk onaylar, ortakl\u0131klardan gelir \u00fcretimi<\/li> <li><strong>2030 Vizyonu<\/strong>: 150-250 $ aral\u0131\u011f\u0131 (+%507 ila +%912)<br> Uzun vadeli: Kurulu \u00fcr\u00fcn portf\u00f6y\u00fc, olas\u0131 sat\u0131n alma hedefi<\/li> <\/ul> <p>Ortalama analist fiyat hedefi olan 90,63 $, mevcut seviyelerden <strong>%267 y\u00fckseli\u015f potansiyeli<\/strong> temsil etmekte olup, JANX'i biyotek sekt\u00f6r\u00fcndeki en cazip risk-getiri f\u0131rsatlar\u0131ndan biri yapmaktad\u0131r.<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyotek Volatilitesinde Yol Alma<\/h2> <h3>Y\u00fcksek Etkili Riskler<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Faz 1\/2 \u015firketi olarak, olumsuz deneme sonu\u00e7lar\u0131 de\u011ferin %50-70'ini bir gecede silebilir<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA gecikmeleri veya reddetmeleri ila\u00e7 geli\u015ftirmede s\u00fcrekli tehditlerdir<\/li> <li><strong>Nakit Yakma Endi\u015feleri<\/strong>: Y\u0131ll\u0131k 105 milyon $ zarar ile ikincil halka arz yoluyla seyrelme riski ger\u00e7ek<\/li> <li><strong>Rekabet Ortam\u0131<\/strong>: Benzer T-h\u00fccre ba\u011flay\u0131c\u0131 teknolojiler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li> <\/ul> <h3>2025 \u0130\u00e7in Pozitif Kataliz\u00f6rler<\/h3> <ul> <li><strong>Pipeline \u0130lerlemesi<\/strong>: JANX007 Faz 1b geni\u015fletme \u00e7al\u0131\u015fmalar\u0131 umut verici g\u00fcvenlik profilleri g\u00f6steriyor<\/li> <li><strong>Platform Geni\u015flemesi<\/strong>: Otoimm\u00fcn hastal\u0131klar i\u00e7in yeni ARM platformu ek pazarlar a\u00e7\u0131yor<\/li> <li><strong>Ortakl\u0131k Potansiyeli<\/strong>: Mevcut Merck i\u015fbirli\u011fi olumlu verilerle geni\u015fleyebilir<\/li> <li><strong>Piyasa Zamanlamas\u0131<\/strong>: Biyotek sekt\u00f6r\u00fc uzun s\u00fcren d\u00fc\u015f\u00fc\u015f sonras\u0131 toparlanma belirtileri g\u00f6steriyor<\/li> <li><strong>Analist Deste\u011fi<\/strong>: 90 $+ fiyat hedefleriyle g\u00fc\u00e7l\u00fc al\u0131m notlar\u0131 kurumsal destek sa\u011fl\u0131yor<\/li> <\/ul> <h2>\ud83d\udcca Ad\u0131m Ad\u0131m: Janux Therapeutics (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Arac\u0131 Kurum Se\u00e7eneklerini Ara\u015ft\u0131r\u0131n<\/td> <td>NASDAQ eri\u015fimi ve rekabet\u00e7i komisyon oranlar\u0131 sa\u011flamak i\u00e7in<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Fonlama<\/td> <td>Biyotek volatilitesi g\u00f6z \u00f6n\u00fcnde bulundurularak y\u00f6netilebilir sermaye ile ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>Sipari\u015f T\u00fcr\u00fc Se\u00e7imi<\/td> <td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/td> <td>Portf\u00f6y\u00fcn sadece %2-5'ini y\u00fcksek riskli biyotek isimlere ay\u0131r\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>Takip Kurulumu<\/td> <td>Klinik deneme duyurular\u0131 ve kazan\u00e7 tarihleri i\u00e7in uyar\u0131lar ayarlay\u0131n<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option'\u0131n Biyotek Yat\u0131r\u0131m\u0131 \u0130\u00e7in \u00d6ne \u00c7\u0131kma Nedenleri<\/h2> <p>Janux Therapeutics gibi yenilik\u00e7i \u015firketlerde pozisyon olu\u015fturmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, biyotek yat\u0131r\u0131m stratejileriyle m\u00fckemmel uyum sa\u011flayan belirgin avantajlar sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, volatil biyotek hisselerinde \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan yat\u0131r\u0131m teorilerini test edebilirsiniz<\/li> <li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: Tek belge KYC s\u00fcreci, klinik deneme sonu\u00e7lar\u0131 veya kazan\u00e7 duyurular\u0131 etraf\u0131ndaki ani fiyat hareketlerinden yararlanman\u0131z\u0131 sa\u011flar<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100'den fazla y\u00f6ntem, biyotek hisselerinin karakteristik h\u0131zl\u0131 de\u011fer art\u0131\u015f\u0131 d\u00f6nemlerinde karlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim sa\u011flar<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engelleri, geleneksel arac\u0131 kurum karma\u015f\u0131kl\u0131klar\u0131 olmadan y\u00fcksek potansiyelli biyotek isimlere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h2>\ud83e\uddec Janux Therapeutics: Kanser Tedavisinde Devrim<\/h2> <p>Janux Therapeutics, t\u00fcm\u00f6r-aktif imm\u00fcnoterapiler alan\u0131nda \u00f6nc\u00fc olarak, kanser bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilecek tedaviler geli\u015ftirmektedir. Sahip olduklar\u0131 TRACTr platformu, sadece t\u00fcm\u00f6r ortamlar\u0131nda T h\u00fccrelerini aktive ederek etkinli\u011fi maksimize ederken sistemik toksisiteyi en aza indiren \u00e7\u0131\u011f\u0131r a\u00e7an bir yakla\u015f\u0131md\u0131r.<\/p> <ul> <li><strong>G\u00fcncel Piyasa Konumu<\/strong>: 1,53 milyar $ piyasa de\u011feri, ko\u015fullu T-h\u00fccre ba\u011flay\u0131c\u0131 teknolojide y\u00fckselen lider konumunda<\/li> <li><strong>Pipeline G\u00fcc\u00fc<\/strong>: \u0130ki klinik a\u015fama varl\u0131\u011f\u0131 (JANX007 ve JANX008) b\u00fcy\u00fck kanser endikasyonlar\u0131n\u0131 hedefliyor<\/li> <li><strong>Yenilik Avantaj\u0131<\/strong>: Yak\u0131n zamanda ARM platformu ile otoimm\u00fcn hastal\u0131klara geni\u015fleyerek onkolojinin \u00f6tesinde \u00e7e\u015fitlendirme<\/li> <\/ul> <h3>\ud83c\udfaf \u0130lgin\u00e7 Ger\u00e7ek 2025<\/h3> <p>Janux Therapeutics, Temmuz 2025'te Ar-Ge ekibinde eski NASA bilim insanlar\u0131n\u0131n bulundu\u011funu a\u00e7\u0131klad\u0131\u011f\u0131nda man\u015fetlere \u00e7\u0131kt\u0131. Bu ekip, ila\u00e7 geli\u015ftirmede havac\u0131l\u0131k hassas m\u00fchendislik prensiplerini uygulayarak analistlerin \"sekt\u00f6rdeki en matematiksel olarak hassas imm\u00fcnoterapi platformu\" olarak adland\u0131rd\u0131\u011f\u0131 bir sistem yaratt\u0131.<\/p> <h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <p><strong>Ciddi \u00d6neriler:<\/strong><\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: \u00d6n\u00fcm\u00fczdeki iki ay boyunca dolar maliyeti ortalamas\u0131 y\u00f6ntemiyle portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2'si kadar pilot pozisyon a\u00e7\u0131n<\/li> <li><strong>Uyar\u0131lar Kurun<\/strong>: 28 $ \u00fczeri k\u0131r\u0131lmalar (onay) ve 22 $ alt\u0131 d\u00fc\u015f\u00fc\u015fler (risk y\u00f6netimi) i\u00e7in fiyat bildirimleri ayarlay\u0131n<\/li> <li><strong>Takvime \u0130\u015faretleyin<\/strong>: 5 Kas\u0131m 2025 kazan\u00e7 tarihini potansiyel f\u0131rsat eklemeleri i\u00e7in i\u015faretleyin<\/li> <\/ol> <p><strong>Esprili Tecr\u00fcbeli Yorum<\/strong>: \"JANX gibi biyotek hisseleriyle i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014son derece heyecan verici potansiyel, ancak deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde duygusal dalgalanmalara haz\u0131rl\u0131kl\u0131 olun. Anahtar, bilimde o kadar \u00e7ok inanmak ki ruh hali de\u011fi\u015fimlerini atlatabilmek!\"<\/p> <p>\u00c7ekici de\u011ferleme, yenilik\u00e7i teknoloji ve sekt\u00f6r toparlanma zamanlamas\u0131n\u0131n birle\u015fimi, Janux Therapeutics'i biyotek volatilitesini benimsemeye istekli yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel olarak ola\u011fan\u00fcst\u00fc getiriler sunan b\u00fcy\u00fcleyici bir f\u0131rsat haline getiriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Fiyat Analizi<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla Janux Therapeutics (JANX) hisseleri <strong>24,70 $<\/strong> seviyesinde i\u015flem g\u00f6rmekte olup, 52 haftal\u0131k aral\u0131\u011f\u0131n\u0131n 21,97 $ ile 71,71 $ aras\u0131ndaki alt s\u0131n\u0131r\u0131na yak\u0131n konumlanm\u0131\u015ft\u0131r. Bu fiyat noktas\u0131, \u015firketin uzun vadeli vizyonuna inanan yat\u0131r\u0131mc\u0131lar i\u00e7in ilgi \u00e7ekici bir giri\u015f f\u0131rsat\u0131 sunmaktad\u0131r.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>5 Kas\u0131m 2025<\/strong> tarihini i\u015faretleyin\u2014bir sonraki kazan\u00e7 a\u00e7\u0131klama tarihi. Tarihsel veriler, JANX&#8217;in \u00e7eyreklik raporlar etraf\u0131nda \u00f6nemli fiyat hareketleri ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. 7 A\u011fustos 2025&#8217;teki \u00f6nceki kazan\u00e7lar %17 EPS sapmas\u0131yla sonu\u00e7land\u0131 (-0,55 $ ger\u00e7ekle\u015fen vs. -0,47 $ beklenen), ancak analist g\u00f6r\u00fc\u015fleri 12 al\u0131m ve sadece bir tut \u00f6nerisi ile h\u00e2l\u00e2 son derece olumlu.<\/p>\n<h3>Kazan\u00e7 Tepkisi Tarih\u00e7esi Analizi<\/h3>\n<p>Son alt\u0131 kazan\u00e7 olay\u0131n\u0131 incelemek ilgin\u00e7 desenler ortaya koymaktad\u0131r:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>\u00d6nemli \u0130\u00e7g\u00f6r\u00fc<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>25,50 $<\/td>\n<td>%-3,1 (1 hafta)<\/td>\n<td>EPS sapmas\u0131 ancak analist g\u00fcveni korundu<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>28,40 $<\/td>\n<td>%+5,6 (3 g\u00fcn)<\/td>\n<td>Beklentileri %2,56 a\u015ft\u0131<\/td>\n<\/tr>\n<tr>\n<td>27 \u015eub 2025<\/td>\n<td>4. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>32,10 $<\/td>\n<td>%+8,2 (1 hafta)<\/td>\n<td>\u00d6nemli %20 EPS a\u015f\u0131m\u0131<\/td>\n<\/tr>\n<tr>\n<td>5 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>45,20 $<\/td>\n<td>%-18,3 (2 hafta)<\/td>\n<td>B\u00fcy\u00fck %54,55 EPS sapmas\u0131<\/td>\n<\/tr>\n<tr>\n<td>8 A\u011fu 2024<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>48,70 $<\/td>\n<td>%+12,1 (1 hafta)<\/td>\n<td>G\u00fc\u00e7l\u00fc klinik ilerleme g\u00fcncellemesi<\/td>\n<\/tr>\n<tr>\n<td>9 May 2024<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>42,30 $<\/td>\n<td>%-6,8 (5 g\u00fcn)<\/td>\n<td>Karma\u015f\u0131k deneme sonu\u00e7lar\u0131 tepkisi<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Desen, kazan\u00e7 sapmalar\u0131n\u0131n k\u0131sa vadeli volatiliteye neden oldu\u011funu ancak hissenin klinik pipeline ilerlemesine ba\u011fl\u0131 olarak \u00e7eyreklik finansal performanstan ba\u011f\u0131ms\u0131z \u015fekilde toparlanma e\u011filiminde oldu\u011funu g\u00f6stermektedir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd04 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2>\n<p>Janux Therapeutics, son alt\u0131 ayda yakla\u015f\u0131k <strong>%63<\/strong> d\u00fc\u015f\u00fc\u015f ya\u015fayarak Aral\u0131k 2024 zirvesi olan 66,83 $ seviyesinden geriledi. Ancak, son d\u00f6nemdeki istikrar potansiyel dip olu\u015fumuna i\u015faret etmektedir:<\/p>\n<ul>\n<li><strong>Ocak 2025<\/strong>: 61,59 $ ile ba\u015flad\u0131, 39,33 $ ile kapand\u0131 (-%18,79) &#8211; Tatil sonras\u0131 d\u00fczeltme<\/li>\n<li><strong>\u015eubat 2025<\/strong>: 31,69 $-45,79 $ aral\u0131\u011f\u0131nda (-%24,36) &#8211; Biyotek sekt\u00f6r\u00fcndeki zay\u0131flama devam etti<\/li>\n<li><strong>Mart 2025<\/strong>: 26,39 $-33,49 $ aral\u0131\u011f\u0131nda istikrar sa\u011flad\u0131 (-%17,91) &#8211; \u0130lk destek bulundu<\/li>\n<li><strong>Nisan 2025<\/strong>: 22,52 $&#8217;den 33,51 $&#8217;e y\u00fckseldi (+%22,96) &#8211; Ar-Ge G\u00fcn\u00fc iyimserli\u011fi<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 22,48 $-33,97 $ aral\u0131\u011f\u0131nda geri \u00e7ekilme (-%28,31) &#8211; Kar realizasyonu a\u015famas\u0131<\/li>\n<li><strong>Haziran 2025<\/strong>: 22,54 $-27,28 $ aral\u0131\u011f\u0131nda konsolidasyon (-%2,94) &#8211; Taban olu\u015fturma<\/li>\n<li><strong>Temmuz 2025<\/strong>: 22,74 $&#8217;den 26,39 $&#8217;e toparlanma (+%13,33) &#8211; Tersine d\u00f6n\u00fc\u015f\u00fcn erken i\u015faretleri<\/li>\n<\/ul>\n<p>Hisse, 22-25 $ aral\u0131\u011f\u0131nda g\u00fc\u00e7l\u00fc destek olu\u015fturuyor gibi g\u00f6r\u00fcnmekte ve son y\u00fckseli\u015f momentumu a\u015f\u0131r\u0131 sat\u0131m ko\u015fullar\u0131ndan potansiyel d\u00f6n\u00fc\u015f\u00fc i\u015faret etmektedir.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik pipeline ilerlemesine dayanarak, gelecekte \u015funlar beklenebilir:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 40-55 $ aral\u0131\u011f\u0131 (+%62 ila +%123) &#8211; <strong>AL<\/strong> \u00f6nerisi<br \/> Kataliz\u00f6rler: Ek JANX007 veri sunumlar\u0131, ARM platformu IND ilerlemesi<\/li>\n<li><strong>2026 Hedefi<\/strong>: 65-85 $ aral\u0131\u011f\u0131 (+%163 ila +%244)<br \/> Potansiyel: Faz 2 veri sonu\u00e7lar\u0131, ortakl\u0131k geni\u015flemeleri<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 90-130 $ aral\u0131\u011f\u0131 (+%264 ila +%426)<br \/> B\u00fcy\u00fcme fakt\u00f6rleri: Olas\u0131 ilk onaylar, ortakl\u0131klardan gelir \u00fcretimi<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 150-250 $ aral\u0131\u011f\u0131 (+%507 ila +%912)<br \/> Uzun vadeli: Kurulu \u00fcr\u00fcn portf\u00f6y\u00fc, olas\u0131 sat\u0131n alma hedefi<\/li>\n<\/ul>\n<p>Ortalama analist fiyat hedefi olan 90,63 $, mevcut seviyelerden <strong>%267 y\u00fckseli\u015f potansiyeli<\/strong> temsil etmekte olup, JANX&#8217;i biyotek sekt\u00f6r\u00fcndeki en cazip risk-getiri f\u0131rsatlar\u0131ndan biri yapmaktad\u0131r.<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Biyotek Volatilitesinde Yol Alma<\/h2>\n<h3>Y\u00fcksek Etkili Riskler<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: Faz 1\/2 \u015firketi olarak, olumsuz deneme sonu\u00e7lar\u0131 de\u011ferin %50-70&#8217;ini bir gecede silebilir<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA gecikmeleri veya reddetmeleri ila\u00e7 geli\u015ftirmede s\u00fcrekli tehditlerdir<\/li>\n<li><strong>Nakit Yakma Endi\u015feleri<\/strong>: Y\u0131ll\u0131k 105 milyon $ zarar ile ikincil halka arz yoluyla seyrelme riski ger\u00e7ek<\/li>\n<li><strong>Rekabet Ortam\u0131<\/strong>: Benzer T-h\u00fccre ba\u011flay\u0131c\u0131 teknolojiler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Pozitif Kataliz\u00f6rler<\/h3>\n<ul>\n<li><strong>Pipeline \u0130lerlemesi<\/strong>: JANX007 Faz 1b geni\u015fletme \u00e7al\u0131\u015fmalar\u0131 umut verici g\u00fcvenlik profilleri g\u00f6steriyor<\/li>\n<li><strong>Platform Geni\u015flemesi<\/strong>: Otoimm\u00fcn hastal\u0131klar i\u00e7in yeni ARM platformu ek pazarlar a\u00e7\u0131yor<\/li>\n<li><strong>Ortakl\u0131k Potansiyeli<\/strong>: Mevcut Merck i\u015fbirli\u011fi olumlu verilerle geni\u015fleyebilir<\/li>\n<li><strong>Piyasa Zamanlamas\u0131<\/strong>: Biyotek sekt\u00f6r\u00fc uzun s\u00fcren d\u00fc\u015f\u00fc\u015f sonras\u0131 toparlanma belirtileri g\u00f6steriyor<\/li>\n<li><strong>Analist Deste\u011fi<\/strong>: 90 $+ fiyat hedefleriyle g\u00fc\u00e7l\u00fc al\u0131m notlar\u0131 kurumsal destek sa\u011fl\u0131yor<\/li>\n<\/ul>\n<h2>\ud83d\udcca Ad\u0131m Ad\u0131m: Janux Therapeutics (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Arac\u0131 Kurum Se\u00e7eneklerini Ara\u015ft\u0131r\u0131n<\/td>\n<td>NASDAQ eri\u015fimi ve rekabet\u00e7i komisyon oranlar\u0131 sa\u011flamak i\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlama<\/td>\n<td>Biyotek volatilitesi g\u00f6z \u00f6n\u00fcnde bulundurularak y\u00f6netilebilir sermaye ile ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Sipari\u015f T\u00fcr\u00fc Se\u00e7imi<\/td>\n<td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fc<\/td>\n<td>Portf\u00f6y\u00fcn sadece %2-5&#8217;ini y\u00fcksek riskli biyotek isimlere ay\u0131r\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Takip Kurulumu<\/td>\n<td>Klinik deneme duyurular\u0131 ve kazan\u00e7 tarihleri i\u00e7in uyar\u0131lar ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option&#8217;\u0131n Biyotek Yat\u0131r\u0131m\u0131 \u0130\u00e7in \u00d6ne \u00c7\u0131kma Nedenleri<\/h2>\n<p>Janux Therapeutics gibi yenilik\u00e7i \u015firketlerde pozisyon olu\u015fturmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, biyotek yat\u0131r\u0131m stratejileriyle m\u00fckemmel uyum sa\u011flayan belirgin avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak, volatil biyotek hisselerinde \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan yat\u0131r\u0131m teorilerini test edebilirsiniz<\/li>\n<li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: Tek belge KYC s\u00fcreci, klinik deneme sonu\u00e7lar\u0131 veya kazan\u00e7 duyurular\u0131 etraf\u0131ndaki ani fiyat hareketlerinden yararlanman\u0131z\u0131 sa\u011flar<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100&#8217;den fazla y\u00f6ntem, biyotek hisselerinin karakteristik h\u0131zl\u0131 de\u011fer art\u0131\u015f\u0131 d\u00f6nemlerinde karlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim sa\u011flar<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve d\u00fc\u015f\u00fck giri\u015f engelleri, geleneksel arac\u0131 kurum karma\u015f\u0131kl\u0131klar\u0131 olmadan y\u00fcksek potansiyelli biyotek isimlere maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83e\uddec Janux Therapeutics: Kanser Tedavisinde Devrim<\/h2>\n<p>Janux Therapeutics, t\u00fcm\u00f6r-aktif imm\u00fcnoterapiler alan\u0131nda \u00f6nc\u00fc olarak, kanser bak\u0131m\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilecek tedaviler geli\u015ftirmektedir. Sahip olduklar\u0131 TRACTr platformu, sadece t\u00fcm\u00f6r ortamlar\u0131nda T h\u00fccrelerini aktive ederek etkinli\u011fi maksimize ederken sistemik toksisiteyi en aza indiren \u00e7\u0131\u011f\u0131r a\u00e7an bir yakla\u015f\u0131md\u0131r.<\/p>\n<ul>\n<li><strong>G\u00fcncel Piyasa Konumu<\/strong>: 1,53 milyar $ piyasa de\u011feri, ko\u015fullu T-h\u00fccre ba\u011flay\u0131c\u0131 teknolojide y\u00fckselen lider konumunda<\/li>\n<li><strong>Pipeline G\u00fcc\u00fc<\/strong>: \u0130ki klinik a\u015fama varl\u0131\u011f\u0131 (JANX007 ve JANX008) b\u00fcy\u00fck kanser endikasyonlar\u0131n\u0131 hedefliyor<\/li>\n<li><strong>Yenilik Avantaj\u0131<\/strong>: Yak\u0131n zamanda ARM platformu ile otoimm\u00fcn hastal\u0131klara geni\u015fleyerek onkolojinin \u00f6tesinde \u00e7e\u015fitlendirme<\/li>\n<\/ul>\n<h3>\ud83c\udfaf \u0130lgin\u00e7 Ger\u00e7ek 2025<\/h3>\n<p>Janux Therapeutics, Temmuz 2025&#8217;te Ar-Ge ekibinde eski NASA bilim insanlar\u0131n\u0131n bulundu\u011funu a\u00e7\u0131klad\u0131\u011f\u0131nda man\u015fetlere \u00e7\u0131kt\u0131. Bu ekip, ila\u00e7 geli\u015ftirmede havac\u0131l\u0131k hassas m\u00fchendislik prensiplerini uygulayarak analistlerin &#8220;sekt\u00f6rdeki en matematiksel olarak hassas imm\u00fcnoterapi platformu&#8221; olarak adland\u0131rd\u0131\u011f\u0131 bir sistem yaratt\u0131.<\/p>\n<h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<p><strong>Ciddi \u00d6neriler:<\/strong><\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: \u00d6n\u00fcm\u00fczdeki iki ay boyunca dolar maliyeti ortalamas\u0131 y\u00f6ntemiyle portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2&#8217;si kadar pilot pozisyon a\u00e7\u0131n<\/li>\n<li><strong>Uyar\u0131lar Kurun<\/strong>: 28 $ \u00fczeri k\u0131r\u0131lmalar (onay) ve 22 $ alt\u0131 d\u00fc\u015f\u00fc\u015fler (risk y\u00f6netimi) i\u00e7in fiyat bildirimleri ayarlay\u0131n<\/li>\n<li><strong>Takvime \u0130\u015faretleyin<\/strong>: 5 Kas\u0131m 2025 kazan\u00e7 tarihini potansiyel f\u0131rsat eklemeleri i\u00e7in i\u015faretleyin<\/li>\n<\/ol>\n<p><strong>Esprili Tecr\u00fcbeli Yorum<\/strong>: &#8220;JANX gibi biyotek hisseleriyle i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014son derece heyecan verici potansiyel, ancak deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde duygusal dalgalanmalara haz\u0131rl\u0131kl\u0131 olun. Anahtar, bilimde o kadar \u00e7ok inanmak ki ruh hali de\u011fi\u015fimlerini atlatabilmek!&#8221;<\/p>\n<p>\u00c7ekici de\u011ferleme, yenilik\u00e7i teknoloji ve sekt\u00f6r toparlanma zamanlamas\u0131n\u0131n birle\u015fimi, Janux Therapeutics&#8217;i biyotek volatilitesini benimsemeye istekli yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel olarak ola\u011fan\u00fcst\u00fc getiriler sunan b\u00fcy\u00fcleyici bir f\u0131rsat haline getiriyor.<\/p>\n"},"faq":[{"question":"Janux Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Janux Therapeutics hisseleri sat\u0131n almak i\u00e7in \u00f6ncelikle NASDAQ eri\u015fimi olan bir arac\u0131 kurumda hesap a\u00e7mal\u0131, hesab\u0131n\u0131z\u0131 fonlamal\u0131, limit emirleri kullanarak uygun fiyatlardan al\u0131m yapmal\u0131 ve portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesini bu y\u00fcksek riskli hisseye ay\u0131rmal\u0131s\u0131n\u0131z."},{"question":"Janux Therapeutics'in riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay s\u00fcre\u00e7lerindeki gecikmeler, y\u00fcksek nakit yakma oran\u0131 ve b\u00fcy\u00fck ila\u00e7 \u015firketleriyle rekabet yer almaktad\u0131r."},{"question":"Janux Therapeutics'in gelecekteki fiyat beklentisi nedir?","answer":"Analistlerin ortalama fiyat hedefi 90,63 $ olup, 2025-2030 aras\u0131nda %267'ye varan y\u00fckseli\u015f potansiyeli \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Pocket Option biyotek yat\u0131r\u0131m\u0131 i\u00e7in neden tercih edilmelidir?","answer":"Pocket Option, d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunarak biyotek hisselerine yat\u0131r\u0131m yapmak isteyenler i\u00e7in uygun bir platformdur."},{"question":"Janux Therapeutics'in yenilik\u00e7i teknolojisi nedir?","answer":"Janux Therapeutics, TRACTr platformu ile t\u00fcm\u00f6r ortam\u0131nda sadece T h\u00fccrelerini aktive ederek y\u00fcksek etkinlik ve d\u00fc\u015f\u00fck toksisite sa\u011flayan yenilik\u00e7i bir imm\u00fcnoterapi geli\u015ftirmektedir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Janux Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Janux Therapeutics hisseleri sat\u0131n almak i\u00e7in \u00f6ncelikle NASDAQ eri\u015fimi olan bir arac\u0131 kurumda hesap a\u00e7mal\u0131, hesab\u0131n\u0131z\u0131 fonlamal\u0131, limit emirleri kullanarak uygun fiyatlardan al\u0131m yapmal\u0131 ve portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesini bu y\u00fcksek riskli hisseye ay\u0131rmal\u0131s\u0131n\u0131z."},{"question":"Janux Therapeutics'in riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay s\u00fcre\u00e7lerindeki gecikmeler, y\u00fcksek nakit yakma oran\u0131 ve b\u00fcy\u00fck ila\u00e7 \u015firketleriyle rekabet yer almaktad\u0131r."},{"question":"Janux Therapeutics'in gelecekteki fiyat beklentisi nedir?","answer":"Analistlerin ortalama fiyat hedefi 90,63 $ olup, 2025-2030 aras\u0131nda %267'ye varan y\u00fckseli\u015f potansiyeli \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Pocket Option biyotek yat\u0131r\u0131m\u0131 i\u00e7in neden tercih edilmelidir?","answer":"Pocket Option, d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve \u00e7ok say\u0131da para \u00e7ekme se\u00e7ene\u011fi sunarak biyotek hisselerine yat\u0131r\u0131m yapmak isteyenler i\u00e7in uygun bir platformdur."},{"question":"Janux Therapeutics'in yenilik\u00e7i teknolojisi nedir?","answer":"Janux Therapeutics, TRACTr platformu ile t\u00fcm\u00f6r ortam\u0131nda sadece T h\u00fccrelerini aktive ederek y\u00fcksek etkinlik ve d\u00fc\u015f\u00fck toksisite sa\u011flayan yenilik\u00e7i bir imm\u00fcnoterapi geli\u015ftirmektedir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T15:56:00+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T15:56:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\",\"name\":\"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"datePublished\":\"2025-08-20T15:56:00+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T15:56:00+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T15:56:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/","name":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","datePublished":"2025-08-20T15:56:00+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-janux-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Janux Therapeutics, Inc. (JANX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Janux Therapeutics, Inc. (JANX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":341913,"slug":"how-to-buy-janux-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Janux Therapeutics, Inc. (JANX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Janux Therapeutics, Inc. (JANX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-janux-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":341912,"slug":"how-to-buy-janux-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Janux Therapeutics, Inc. (JANX) - Investimento em a\u00e7\u00f5es da Janux Therapeutics, Inc. (JANX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-janux-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=341907"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/341907\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334009"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=341907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=341907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=341907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}